Enanta Pharmaceuticals Inc. has patented compounds acting as nonstructural protein 3 (nsp3, PL-pro; SARS-CoV-2) inhibitors reported to be useful for the treatment of asthma, SARS-CoV-2 infection (COVID-19), rhinovirus, norovirus and lung infections.
Muscle fatigue associated with brain inflammation could be prevented by modulating certain cytokines. Researchers at Washington University in St. Louis (WUSTL) have studied inflammation in the CNS in infection models of Escherichia coli, SARS-CoV-2 and amyloid-β toxicity, unveiling its impact on motor function, the role of IL-6 in this process and how to mitigate it in chronic disease.
Researchers from Children’s Hospital Boston and affiliated organizations have reported the discovery and preclinical characterization of a novel TLR7/8 agonist adjuvant for vaccination, PVP-037.
Pfizer Inc. has identified nonstructural protein 3 (nsp3; PLpro) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 (COVID-19) infection.
Merck Sharp & Dohme LLC has described 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV and SARS-CoV-2 infection (COVID-19).
Enanta Pharmaceuticals Inc. has divulged macrocyclic chalcone-amide compounds acting as non-structural protein 3 (nsp3; PL-pro) (SARS-CoV-2; COVID-19 virus) inhibitors.
The granting of emergency use authorization by the U.S. FDA to Roche AG for its four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and respiratory syncytial virus will allow the company to quickly bring the test to near-patient care environments ahead of the flu season, to address a real need in the marketplace, Ian Parfrement, head of the point of care customer area, at Roche Diagnostics, told BioWorld.
Schrodinger Inc. and Takeda Pharmaceutical Co. Ltd. have identified 3C-like proteinase (3CLpro; Mpro; nsp5) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome.
Emory University has identified 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
